Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 7/20 | 0.48 |
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20418994 | 0.85 | RIPK1 (0.70) | TSHRHIF1ACYP2D6RIPK1CA2 | |
| SCHEMBL15471188 | 0.82 | ALDH1A1 (0.60) | RIPK1CA2POLBKDM4EMAPT | |
| SCHEMBL8061739 | 0.82 | TSHR (0.52) | TSHRHIF1ACYP2D6RIPK1CA2 | |
| SCHEMBL12205752 | 0.81 | RIPK1 (0.43) | TSHRHIF1ACYP2D6RIPK1CA2 | |
| SCHEMBL19318518 | 0.81 | HPGD (0.53) | CYP2D6RIPK1CA2CA1CA7 | |
| SCHEMBL13726222 | 0.81 | RIPK1 (0.74) | TSHRRIPK1MAPTSMN1; SMN2 | |
| SCHEMBL8985034 | 0.80 | POLB (0.65) | TSHRPOLBHSD17B10MAPTAKR1B1 | |
| SCHEMBL4362706 | 0.79 | TSHR (0.57) | TSHRHIF1ACYP2D6CA2CA12 | |
| SCHEMBL14782975 | 0.79 | HTT (0.53) | TSHRHIF1ARIPK1CA12CA9 | |
| SCHEMBL13911836 | 0.79 | RIPK1 (0.42) | TSHRHIF1ACYP2D6RIPK1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220000847-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11053216-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200071296-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2020-03-05 | — | — | US | disclosed |
| US-20180208577-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-07-26 | — | — | US | disclosed |
| US-10030004-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030004-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-20160326137-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000847-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | TSHR 3502/4885HIF1A 751/4885CYP2D6 4782/4885 |
| US-11702401-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | TSHR 3502/4885HIF1A 751/4885CYP2D6 4782/4885 |
| US-10030004-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | TSHR 3502/4885HIF1A 751/4885CYP2D6 4782/4885 |
| US-20160326137-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | TSHR 3502/4885HIF1A 751/4885CYP2D6 4782/4885 |
| US-20200071296-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | TSHR 3502/4885HIF1A 751/4885CYP2D6 4782/4885 |
| US-11053216-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | TSHR 3502/4885HIF1A 751/4885CYP2D6 4782/4885 |
| US-20180208577-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | TSHR 3502/4885HIF1A 751/4885CYP2D6 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.